Evaluation of the MAGLUMI HIV Ab/Ag Combi Test for the Detection of HIV Infection

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2024 Nov 14

PMID 39538348

Authors

Chunling Wang

Jie Rao

Zhonggang Fang

Hongwei Zhang

Jun Yin

Tinghua Li

Chen Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Human immunodeficiency virus (HIV) infection screening and diagnosis are critical to control the HIV epidemic. Testing for anti-HIV antibodies (Ab) and antigens (Ag) in blood samples is the first step to screen people who have been potentially exposed to the virus. This study aimed to evaluate the performance of the MAGLUMI HIV Ab/Ag Combi for detection of HIV antibodies and antigens.

Methods: We used residual samples to assess the diagnostic specificity and sensitivity of the MAGLUMI HIV Ab/Ag Combi retrospectively. All samples that met the test criteria were tested with the MAGLUMI HIV Ab/Ag Combi according to manufacturer's instruction. Results of the MAGLUMI HIV Ab/Ag Combi were compared with the Architect HIV Ag/Ab Combo test.

Results: The specificity of the MAGLUMI HIV Ab/Ag Combi was 99.85% in 5,057 unselected blood donors and 100.00% in 213 hospitalized patient samples, respectively. The sensitivity of the Test in 614 HIV-1 Ab, HIV-1 Ag or HIV-2 Ab positive samples was 100.00%. Seroconversion sensitivity from results of 30 panels was comparable between the MAGLUMI HIV Ab/Ag Combi and the Architect assay.

Conclusions: The reactivity of the MAGLUMI HIV Ab/Ag Combi test is comparable to the Architect HIV Ag/Ab Combo assay.

References

Branson B . HIV Diagnostics: Current Recommendations and Opportunities for Improvement. Infect Dis Clin North Am. 2019; 33(3):611-628. DOI: 10.1016/j.idc.2019.04.001. View

de Souza M, Phanuphak N, Pinyakorn S, Trichavaroj R, Pattanachaiwit S, Chomchey N . Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection. AIDS. 2015; 29(7):793-800. DOI: 10.1097/QAD.0000000000000616. View

Kim S, Kim J, Yoon S, Park Y, Kim H . Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection. J Clin Microbiol. 2008; 46(12):3919-23. PMC: 2593301. DOI: 10.1128/JCM.01603-08. View

White D, Anderson E, Basham K, Ng V, Russell C, Lyons M . Clinical Utility of the Signal-to-Cutoff Ratio of Reactive HIV Antigen/Antibody Screening Tests in Guiding Emergency Physician Management. J Acquir Immune Defic Syndr. 2022; 89(3):332-339. DOI: 10.1097/QAI.0000000000002873. View

Chen Z, Julg B . Therapeutic Vaccines for the Treatment of HIV. Transl Res. 2020; 223:61-75. PMC: 8188575. DOI: 10.1016/j.trsl.2020.04.008. View

Menendez-Arias L, Delgado R . Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2021; 43(1):16-29. DOI: 10.1016/j.tips.2021.10.004. View

Marson K, Marlin R, Pham P, Cohen S, Jones D, Roemer M . Real-world performance of the new US HIV testing algorithm in medical settings. J Clin Virol. 2017; 91:73-78. PMC: 5716467. DOI: 10.1016/j.jcv.2017.04.003. View

Williams A, Menon S, Crowe M, Agarwal N, Biccler J, Bbosa N . Geographic and Population Distributions of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Circulating Subtypes: A Systematic Literature Review and Meta-analysis (2010-2021). J Infect Dis. 2023; 228(11):1583-1591. PMC: 10681860. DOI: 10.1093/infdis/jiad327. View

Smith M, Rutstein S, Powers K, Fidler S, Miller W, Eron Jr J . The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr. 2013; 63 Suppl 2:S187-99. PMC: 4015137. DOI: 10.1097/QAI.0b013e31829871e0. View

10.

Landovitz R, Scott H, Deeks S . Prevention, treatment and cure of HIV infection. Nat Rev Microbiol. 2023; 21(10):657-670. DOI: 10.1038/s41579-023-00914-1. View

11.

Nasrullah M, Wesolowski L, Meyer 3rd W, Owen S, Masciotra S, Vorwald C . Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm. AIDS. 2012; 27(5):731-7. PMC: 4582659. DOI: 10.1097/QAD.0b013e32835bc535. View

12.

Curtis K, Rudolph D, Pan Y, Delaney K, Anastos K, DeHovitz J . Evaluation of the Abbott ARCHITECT HIV Ag/Ab combo assay for determining recent HIV-1 infection. PLoS One. 2021; 16(7):e0242641. PMC: 8248699. DOI: 10.1371/journal.pone.0242641. View

13.

Yarchoan R, Uldrick T . HIV-Associated Cancers and Related Diseases. N Engl J Med. 2018; 378(11):1029-1041. PMC: 6890231. DOI: 10.1056/NEJMra1615896. View

14.

Newman H, Hardie D . HIV-1 viral load testing in resource-limited settings: Challenges and solutions for specimen integrity. Rev Med Virol. 2020; 31(2):e2165. DOI: 10.1002/rmv.2165. View

15.

Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S . Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2018; 19(2):143-155. DOI: 10.1016/S1473-3099(18)30647-9. View

16.

Fei C, Ye A, Zhang J . [Evaluation of different methods in determination of low level HBsAg]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011; 40(4):436-9. DOI: 10.3785/j.issn.1008-9292.2011.04.016. View

17.

Williamson P, Jarvis J, Panackal A, Fisher M, Molloy S, Loyse A . Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol. 2016; 13(1):13-24. DOI: 10.1038/nrneurol.2016.167. View

18.

Lemee V, Greaume S, Gautier J, Dzamitika S, Coignard C, Jortani S . Performance evaluation of the new Access HIV Ag/Ab combo assay on the DxI 9000 Access Immunoassay Analyzer. J Clin Virol. 2024; 174:105712. DOI: 10.1016/j.jcv.2024.105712. View

19.

Vallefuoco L, Mazzarella C, Portella G . Fourth generation assays for HIV testing. Expert Rev Mol Diagn. 2016; 16(7):723-32. DOI: 10.1080/14737159.2016.1179115. View

20.

Paraskevis D, Hatzakis A . Global molecular epidemiology of HIV-1: the chameleon challenge. Lancet Infect Dis. 2018; 19(2):114-115. DOI: 10.1016/S1473-3099(18)30687-X. View